Evidence map›Paper›PMID 40547178›Full record

ArticleWorld journal of gastrointestinal oncology2025

Noninvasive prediction of Ki-67 expression in pancreatic cancer

Zi-Yi Yang, Wei-Na Wan, Lei Zhao, Si-Nong Li, Zhe Liu, Liang Sang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zi-Yi YangDepartment of Ultrasonography, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Wei-Na WanDepartment of Ultrasonography, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Lei ZhaoDepartment of Ultrasonography, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Si-Nong LiDepartment of Ultrasonography, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Zhe LiuDepartment of Pancreatic-Biliary Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Liang SangDepartment of Ultrasonography, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China. 20091213@cmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe expression level of Ki-67 and the degree of differentiation in pancreatic cancer determine tumor aggressiveness and patient prognosis, which holds significant implications for clinical decision-making. A major challenge in preoperative pancreatic ductal adenocarcinoma management is predicting tumor malignancy. Contrast-enhanced ultrasound (CEUS), a dynamic imaging technique based on blood pool visualization, can reveal lesion vasculature and provide quantitative perfusion data reflecting angiogenesis. By tracking contrast agent kinetics, CEUS offers non-invasive insights into tumor vascularization, helping assess malignancy potential.

aimTo investigate the correlation between Ki-67 and pancreatic cancer differentiation using CEUS quantitative parameters and evaluated their diagnostic accuracy.

methodsThis retrospective study analyzed pancreatic cancer patients who underwent CEUS and pathological confirmation. Pathological differentiation, clinical data, and quantitative CEUS parameters [maximum intensity (IMAX), rise time (RT), rise slope 50% (Rs50), rise slope 10%-90% (Rs1090),

resultsAmong 54 patients (25 high Ki-67, 29 low Ki-67), significant differences (

conclusionCEUS parameters (Rs50, IMAX, WoutAUC, Rs1090) strongly correlate with Ki-67, aiding non-invasive pancreatic cancer assessment. Rs1090/IMAX predict high Ki-67; Fs50 identifies low Ki-67, supporting CEUS for tumor aggressiveness evaluation.

Indexed as

Contrast-enhanced ultrasoundKi-67 indexPancreatic cancerPathological differentiation degreeQuantitative analysis

Identifiers

PMID40547178
PMCPMC12179939

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.